Molecular diagnostics company Novacyt, listed on London’s junior AIM market, launches a consultation process aimed at potential restructuring, according to multiple reports. The company says that up to two out of five workers could be affected by the changes. The consultation begins on Monday, with the process intended to explore the impact of proposed restructuring measures and possible alternatives. The reports describe the consultation as a formal step the company takes before any job reductions are decided. While details of the specific roles or departments affected are not provided in the available summaries, the figures indicate a potential workforce reduction of around 40% depending on the outcome of consultations. The reporting is consistent across outlets on the company’s sector, its AIM listing, the start of the consultation, and the estimate of how many jobs may be at risk. No additional information is included in the excerpts on the company’s financial performance, the timeline for decisions, or whether the restructuring relates to any particular contracts or business units.